Blood Cancer News and Research

RSS

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

The U.S. House of Representatives today passed House Resolution 1433, declaring September 2010 as 'Blood Cancer Awareness Month.' The resolution helps raise awareness and support for issues affecting blood cancer patients within the halls of the Capitol.

24 Sep 2010

National survey highlights need for greater awareness on lymphoma

While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma.

21 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

Stars join Bupa 30th Great North Run for Leukaemia & Lymphoma Research

Soap stars warm up for Bupa 30th Great North Run for Leukaemia & Lymphoma Research

14 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

New familial link in juvenile myelomonocytic leukemia discovered

A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.

9 Aug 2010

Mount Sinai joins MMRC to develop new treatments for multiple myeloma

The Multiple Myeloma Research Consortium (MMRC) and Mount Sinai School of Medicine today announced that Mount Sinai has become the newest Member Institution to join the MMRC to accelerate the development of new treatments for multiple myeloma.

3 Aug 2010

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Ben-Gurion University of the Negev Professor Varda Shoshan-Barmatz has been awarded a three-year, $600,000 grant from the U.S. Leukemia & Lymphoma Society to develop target-specific, anti-cancer drugs.

2 Aug 2010

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL.

28 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Wyse Technology announces partnership, continued success with LLS

Wyse Technology, the inventor and global leader in cloud client computing, today announced its partnership and continued success with The Leukemia and Lymphoma Society, the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services.

13 Jul 2010

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

The Leukemia & Lymphoma Society today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research research initiative, bringing the program's total funding to $210.5 million since its inception in 2000.

13 Jul 2010

U.S. lags in keeping workers safe from toxic drugs

In many countries, there are strict regulations and inspections regarding workers who handle chemotherapy drugs. "In the U.S., however, neither environmental monitoring nor exposure tracking is mandated. And neither is routinely taking place, said Tom Conner, a research biologist with National Institute for Occupational Safety and Health (NIOSH).

13 Jul 2010

Musashi 2 protein predicts progression of AML and CML, identify researchers

Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia and chronic myeloid leukemia patients.

9 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

News roundup: Judge approves $712 million settlement for 9/11 emergency workers' health problems; Missouri ballot measure on health overhaul challenged

A judge approved a $712 million health settlement for thousands of emergency workers who responded after the Sept. 11 attack, in spite of objections from some who complained that the deal was unfair. Some workers who say they got sick working at the Ground Zero site argued Wednesday that the settlement shortchanged those suffering from certain types of diseases. One of the key factors in how much workers get paid under the settlement, approved by U.S. District Judge Alvin Hellerstein, depends on the type of disease the person contracted.

25 Jun 2010

Blood Cancer News and Research

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

National survey highlights need for greater awareness on lymphoma

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

Stars join Bupa 30th Great North Run for Leukaemia & Lymphoma Research

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

New familial link in juvenile myelomonocytic leukemia discovered

Mount Sinai joins MMRC to develop new treatments for multiple myeloma

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Wyse Technology announces partnership, continued success with LLS

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

U.S. lags in keeping workers safe from toxic drugs

Musashi 2 protein predicts progression of AML and CML, identify researchers

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Japan's MHLW grants full marketing authorization to REVLIMID

News roundup: Judge approves $712 million settlement for 9/11 emergency workers' health problems; Missouri ballot measure on health overhaul challenged

Everything you should know about lymphoma eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News